DRUG INDUCED LIVER INJURY (DILI)

IVTD’s patented human skin stem cell-derived hepatic cell model (hSKP-HPC or HepaSTARs) provides a sensitive and accurate assay for toxicity screening of novel drug candidates and the detection of drug-induced steatosis, phospholipidosis and acute liver failure, and has been tested using compounds with known toxicity, including sodium valproate and paracetamol. The hSKP-HPC model compares favourably with human hepatocytes, HepG2 and HepaRG™ cells in assessing hepatotoxicty. 

PUBLICATIONS

• Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone (2018)
• Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems (2017)
• In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells (2016)
• Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals (2014)
   

SEEKING COLLABORATIONS/CANDIDATES

led by Tamara Vanhaecke

• miniaturisation of DILI prediction in hSKP-HPC model towards high-throughput drug screening